Phospho-MLKL (T357) in Human Squamous Cell Carcinoma. MLKLphosphorylated at T357 was detected in immersion fixed paraffin-embedded sections of human squamous cell carcinoma using Mouse Anti-Human Phospho-MLKL (T357) Monoclonal Antibody (Catalog # MAB9187) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Mixed Lineage Kinase Domain-Like (MLKL) is a 471
amino acid member of the protein kinase superfamily, but lacks several amino
acid residues necessary for kinase activity.
Phosphorylation of MLKL at T357 and S358 by receptor-interacting protein 3 (RIP3)
causes trimerization and translocation of MLKL from the cytosol to the plasma
membrane, where it mediates TNF-alpha induced necroptosis through membrane
degradation and calcium influx. Low
expression of MLKL has been found to be correlated with poor prognosis in
cervical squamous cell carcinoma, pancreatic cancer, and ovarian cancer. Conversely, high expression of RIPK3 and MLKL
in esophageal and colon cancer is associated with poor overall survival, possibly
by promoting inflammatory cytokine production, sustaining tumor growth.